Real-time Estimate
Cboe BZX
12:37:56 2024-05-14 pm EDT
5-day change
1st Jan Change
0.477
USD
+7.38%
-4.23%
-15.82%
Senseonics Holdings, Inc.(NYSEAM:SENS) dropped from Russell Small Cap Completeness Index
June 23, 2023 at 12:00 am EDT
Senseonics Holdings, Inc.(NYSEAM:SENS) dropped from Russell Small Cap Completeness Index
Transcript : Senseonics Holdings, Inc., Q1 2024 Earnings Call, May 13, 2024
May. 13
Earnings Flash (SENS) SENSEONICS HOLDINGS Posts Q1 Revenue $5.1M, vs. Street Est of $4.6M
May. 13
MT
Senseonics Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
May. 13
CI
Senseonics Partners with Rimidi to Develop Innovative Diabetes Solution
May. 09
CI
Senseonics Holdings, Inc. Announces Eversense CGM System Receives iCGM Designation by the U.S. Food and Drug Administration
Apr. 30
CI
Senseonics Holdings, Inc. Announces Board Changes
Mar. 25
CI
Transcript : Senseonics Holdings, Inc., Q4 2023 Earnings Call, Feb 29, 2024
Feb. 29
Senseonics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Feb. 29
CI
Senseonics Holdings, Inc. Provides Revenue Guidance for the First Half of 2024
Feb. 29
CI
Earnings Flash (SENS) SENSEONICS HOLDINGS Posts Q4 Revenue $8M, vs. Street Est of $7.6M
Feb. 29
MT
Senseonics Q4 Revenue Guidance Tops Consensus
Jan. 02
MT
Earnings Flash (SENS) SENSEONICS HOLDINGS Reports Q3 Revenue $6.1M, vs. Street Est of $5.5M
Nov. 09
MT
Senseonics Holdings, Inc. Provides Earnings Guidance for the Year 2023
Nov. 09
CI
Transcript : Senseonics Holdings, Inc., Q3 2023 Earnings Call, Nov 09, 2023
Nov. 09
Senseonics Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 09
CI
Senseonics Holdings, Inc. Announces the Last Patient Completion of the 365-Day ENHANCE Pivotal Clinical Study
23-09-26
CI
Senseonics Holdings, Inc.(NYSEAM:SENS) dropped from S&P Healthcare Equipment Select Industry Index
23-09-18
CI
Senseonics Holdings, Inc. Enters into $50 Million Loan Facility with Hercules Capital, Inc
23-09-11
CI
Senseonics Holdings, Inc. announced that it expects to receive $50 million in funding
23-09-07
CI
Insider Buy: Senseonics Holdings
23-08-31
MT
HC Wainwright Adjusts Senseonics Price Target to $2 From $3, Maintains Buy Rating
23-08-15
MT
Senseonics Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-10
CI
Transcript : Senseonics Holdings, Inc., Q2 2023 Earnings Call, Aug 10, 2023
23-08-10
Senseonics Holdings, Inc. Reiterates Revenue Guidance for the Full Year 2023
23-08-10
CI
Earnings Flash (SENS) SENSEONICS HOLDINGS Reports Q2 Revenue $4.1M, vs. Street Est of $4.49M
23-08-10
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the diabetes community. Its glucose monitoring (CGM) systems, Eversense, Eversense XL, and Eversense E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every five minutes to a mobile app on the user's smartphone. Eversense consists of three primary components: a small sensor inserted subcutaneously under the skin by a healthcare provider; an external removable smart transmitter that receives, assesses and relays data from the sensor and provides vibratory alerts; and a mobile app that receives data from the transmitter and provides real-time glucose readings, alerts and other data the person's mobile device. Its CGM system continually and accurately measures a person's glucose levels for up to six months.
More about the company
Last Close Price
0.4442
USD
Average target price
1.633
USD
Spread / Average Target
+267.70%
Consensus
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1